Literature DB >> 20405856

Classification and virtual screening of androgen receptor antagonists.

Jiazhong Li1, Paola Gramatica.   

Abstract

Computational tools, such as quantitative structure-activity relationship (QSAR), are highly useful as screening support for prioritization of substances of very high concern (SVHC). From the practical point of view, QSAR models should be effective to pick out more active rather than inactive compounds, expressed as sensitivity in classification works. This research investigates the classification of a big data set of endocrine-disrupting chemicals (EDCs)-androgen receptor (AR) antagonists, mainly aiming to improve the external sensitivity and to screen for potential AR binders. The kNN, lazy IB1, and ADTree methods and the consensus approach were used to build different models, which improve the sensitivity on external chemicals from 57.1% (literature) to 76.4%. Additionally, the models' predictive abilities were further validated on a blind collected data set (sensitivity: 85.7%). Then the proposed classifiers were used: (i) to distinguish a set of AR binders into antagonists and agonists; (ii) to screen a combined estrogen receptor binder database to find out possible chemicals that can bind to both AR and ER; and (iii) to virtually screen our in-house environmental chemical database. The in silico screening results suggest: (i) that some compounds can affect the normal endocrine system through a complex mechanism binding both to ER and AR; (ii) new EDCs, which are nonER binders, but can in silico bind to AR, are recognized; and (iii) about 20% of compounds in a big data set of environmental chemicals are predicted as new AR antagonists. The priority should be given to them to experimentally test the binding activities with AR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20405856     DOI: 10.1021/ci100078u

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  7 in total

1.  Integration of in silico methods and computational systems biology to explore endocrine-disrupting chemical binding with nuclear hormone receptors.

Authors:  P Ruiz; A Sack; M Wampole; S Bobst; M Vracko
Journal:  Chemosphere       Date:  2017-03-09       Impact factor: 7.086

2.  Development, validation and integration of in silico models to identify androgen active chemicals.

Authors:  Serena Manganelli; Alessandra Roncaglioni; Kamel Mansouri; Richard S Judson; Emilio Benfenati; Alberto Manganaro; Patricia Ruiz
Journal:  Chemosphere       Date:  2018-12-19       Impact factor: 7.086

3.  Systematic evaluation of supervised classifiers for fecal microbiota-based prediction of colorectal cancer.

Authors:  Luoyan Ai; Haiying Tian; Zhaofei Chen; Huimin Chen; Jie Xu; Jing-Yuan Fang
Journal:  Oncotarget       Date:  2017-02-07

Review 4.  Review of in silico studies dedicated to the nuclear receptor family: Therapeutic prospects and toxicological concerns.

Authors:  Asma Sellami; Manon Réau; Matthieu Montes; Nathalie Lagarde
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-13       Impact factor: 6.055

5.  Combined Naïve Bayesian, Chemical Fingerprints and Molecular Docking Classifiers to Model and Predict Androgen Receptor Binding Data for Environmentally- and Health-Sensitive Substances.

Authors:  Alfonso T García-Sosa; Uko Maran
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

6.  Prediction of acute mammalian toxicity using QSAR methods: a case study of sulfur mustard and its breakdown products.

Authors:  Patricia Ruiz; Gino Begluitti; Terry Tincher; John Wheeler; Moiz Mumtaz
Journal:  Molecules       Date:  2012-07-27       Impact factor: 4.411

7.  Classification of estrogenic compounds by coupling high content analysis and machine learning algorithms.

Authors:  Rajib Mukherjee; Burcu Beykal; Adam T Szafran; Melis Onel; Fabio Stossi; Maureen G Mancini; Dillon Lloyd; Fred A Wright; Lan Zhou; Michael A Mancini; Efstratios N Pistikopoulos
Journal:  PLoS Comput Biol       Date:  2020-09-24       Impact factor: 4.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.